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Targeted therapy has survival benefit for patients with advanced renal cell carcinoma. However,
intolerability often causes discontinuation of treatment. Therefore management of adverse events and
maintenance of treatment duration as long as possible are absolutely essential for patient care.
Hypertension is a common adverse event of vascular endothelial growth factor receptor (VEGFR) inhibitors.
General symptoms such as fatigue or asthenia and gastrointestinal disorders including diarrhea, nausea, and
anorexia are also frequently produced by VEGFR inhibitors as well as other targeted agents under
development. Development of a new drug which does not cause any severe adverse event may be an
ultimate strategy against adverse events of current targeted agents. Here we review the adverse-event
profiles of targeted therapies being developed, including axitinib, tivozanib, dovitinib, AS1411, vorinostat,
AMG386, BMS-936558, carfilzomib, IMA901, and AGS-003, for renal cell carcinoma.
(Hinyokika Kiyo 58 : 655-657, 2012)
























Table 1. Agents being developed for advanced
renal cell carcinoma
Target Drug Status
VEGFR Pazopanib Approved in EU and US
Axitinib Approved in Japan, Switzerland,and US
Tivozanib Ph III ongoing
Dovitinib Ph III ongoing
Linifanib Ph II ongoing
AKT MK-2206 Ph II ongoing
Nucleolin AS1411 Ph II ongoing
Histone
deacetylase Vorinostat Ph II ongoing
Tie2 AMG386 Ph II ongoing
PD-1 BMS-936558 Ph II ongoing
Proteasome Carfilzomib Ph Ib/II ongoing
Tubulin BNC105P Ph I/II ongoing
Vaccine IMA901 Ph III ongoing
AGS-003 Ph II ongoing
MGN1601 Ph I/II ongoing















（ 4％），下痢（ 3％），無力症（ 3％）であった．グ
レード 3以上の血液検査値異常は ALT 上昇（12％），







Axitinib も pazopanib と同様の分子を標的とするが，


























Dovitinib の特徴は VEGFR や PDGFR など以外に
線維芽細胞増殖因子受容体 (FGFR) を阻害する点で
ある．VEGFR 阻害薬および/あるいは mTOR 阻害薬
による治療歴のある腎細胞癌患者を対象とした第Ⅱ相
臨床試験において頻度の高かった有害事象は，嘔気














ンは bcl-2 mRNAの 3’ 非翻訳領域にある A＋U を豊富
に含む不安定エレメントに結合し，bcl-2 mRNA を分






























BMS-936558 (MDX-1106/ONO-4538) は PD-1 に対
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